Workshop A Tuesday, October 15

9:00 am - 12:00 pm
Utilising Incentives to Develop Gene Therapies in the Rare Disease Space

Gaining access to incentives is essential in facilitating the drug development in the rare disease space. With so many different options available and strategies to utilise these incentives, guidance on best practices and case-studies of effective use of incentives are invaluable. This workshop will share a comprehensive insight into the incentives that are available, enabling you to move forward with more clarity.

Attend this workshop to learn about:
  • How to best use incentives and guides for working in the rare disease space
  • Investigating at what time in development to utilise incentives
  • Comprehensive insights into:

– Regulatory pathways
– Developmental practices
– Financial incentives

Workshop Leader: Diego Ardigo, R&D Rare Diseases Unit Head, Chiesi & Chairman, Therapies Scientific Committee, IRDIRC

Workshop B Tuesday, October 15

1:00 pm - 4:00 pm
Gearing Up for Commercialisation from Early in Development

More gene therapies are reaching the late stages of clinical development and gaining approvals, both in th US and EU. It’s clear however that the decisions to support commercialisation can’t be left until the point of approval, and that factors like investment, interaction with regulators and key hires need to be considered as part of the work in gearing up for commercialisation.

Attend this workshop to learn about:

  • Understanding the commercial decisions that need to be considered early on in development to prepare for future commercialisation
  • Improving communication strategies to disseminate commercially-valuable information within organisations to prepare for future commercialisation more effectively
  • Investigate the key commercial decisions that need to be made, including:

– When to interact with regulators
– Key hires to advance towards commercial objectives
– Fundraising methods
– Key processes to put in place

Workshop Leaders: Sven Kili, Principle, Sven Kili Consulting & Marcus Peters, Former CCO, Agilis Biotherapeutics